Analyst Expectations for Blueprint Medicines's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 18 analysts have published their opinions on Blueprint Medicines (NASDAQ:BPMC) stock, with an average 12-month price target of $74.06. The average price target has increased by 25.76% over the past month.
May 23, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines (NASDAQ:BPMC) has an average 12-month price target of $74.06, with the target increasing by 25.76% over the past month.
The average 12-month price target for Blueprint Medicines has increased by 25.76% over the past month, indicating a positive sentiment among analysts. This could lead to a short-term increase in the stock price as investors react to the updated price targets.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100